SERPINE1 and breast carcinoma: To the best of our knowledge, uPA and PAI-1 are the first breast cancer biomarkers to have their prognostic and predictive utility validated in either a randomized prospective trial or a pooled analysis of individualized data from both published and unpublished data (that is, in two independent LOE-1 studies) [5,6].